Fixed low-dose combinations of an AT1-receptor blocker and a thiazide diuretic provide synergistic blood pressure lowering and mitigate undesirable metabolic effects, supporting their use as first- or second-line therapy for hypertension.
Answers are grounded in this paper and cite their sources.
Supports ARB-thiazide combinations for hypertension; leaves open need for outcome-focused RCTs before broad first-line adoption.
Treatment of hypertension remains a difficult task despite the availability of different types of medications lowering blood pressure by different mechanisms. In order to reach the target blood pressures recommended today combination therapy is required in most patients. The co-administration of two drugs with different impacts on the cardiovascular system markedly increases the antihypertensive effectiveness without altering adversely tolerability. Fixed low-dose combinations are becoming a valuable option not only as second-line, but also as first-line therapy. In this respect the co-administration of thiazide diuretic with an AT(1)-receptor blocker is particularly appealing. The diuretic-induced decrease in total body sodium activates the renin-angiotensin system, thus rendering blood pressure maintenance angiotensin II-dependent. During blockade of the renin-angiotensin system low doses of thiazides generally suffice, allowing the prevention of undesirable metabolic effects. Also, blockade of the AT(1)-receptor, particularly when angiotensin II production is enhanced in response to diuretic therapy, is expected to be beneficial, since angiotensin II seems to contribute importantly to the pathogenesis of cardiovascular and renal complications of hypertension.
No takes yet. Share an insight, caveat, or question.
Bernard Waeber (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: